Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated at Deutsche Bank Aktiengesellschaft

Analysts at Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a note issued to investors on Tuesday,Briefing.com Automated Import reports. The firm set a “hold” rating and a $136.00 price target on the biotechnology company’s stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential upside of 20.63% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Robert W. Baird lowered their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Jefferies Financial Group began coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They issued a “buy” rating and a $165.00 price target for the company. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research report on Monday, January 27th. Finally, Evercore ISI decreased their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $176.77.

Sarepta Therapeutics Price Performance

SRPT opened at $112.74 on Tuesday. The stock has a 50-day moving average price of $120.82 and a 200-day moving average price of $125.57. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a market cap of $10.77 billion, a PE ratio of 90.19 and a beta of 0.75. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high of $173.25.

Insider Activity

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now owns 5,880 shares in the company, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. Truist Financial Corp grew its stake in Sarepta Therapeutics by 86.5% in the second quarter. Truist Financial Corp now owns 4,003 shares of the biotechnology company’s stock valued at $632,000 after purchasing an additional 1,857 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 197 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Sarepta Therapeutics by 896.5% during the third quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 511 shares during the last quarter. Bank Pictet & Cie Europe AG grew its stake in shares of Sarepta Therapeutics by 27.7% during the third quarter. Bank Pictet & Cie Europe AG now owns 2,827 shares of the biotechnology company’s stock worth $353,000 after acquiring an additional 613 shares during the last quarter. Finally, International Assets Investment Management LLC grew its stake in shares of Sarepta Therapeutics by 59,222.7% during the third quarter. International Assets Investment Management LLC now owns 75,933 shares of the biotechnology company’s stock worth $9,483,000 after acquiring an additional 75,805 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.